Drug that cuts risk of breast cancer returning is approved for use in England
Up to 4,000 patients a year with early stage of disease could receive ribociclib, but charities want wider access to drug
Thousands of women with early breast cancer could be offered a drug to stop the cancer returning, after the medicines watchdog approved its use in England.
Up to 4,000 patients a year could be given ribociclib alongside hormone therapy, for hormone receptor-positive, HER2-negative early breast cancer, which despite initial treatment has a higher risk of returning.
Cancer present in at least four lymph nodes.
Cancer present in one to three lymph nodes that is either grade 3 (more advanced), or has a primary tumour at least 5cm in size.
Continue reading...
By Anna Bawden Health and social affairs corespondent
Drug that cuts risk of breast cancer returning is approved for use in England to Continue reading...
NHS Forums - For NHS Staff | Patient Forums
Up to 4,000 patients a year with early stage of disease could receive ribociclib, but charities want wider access to drug
Thousands of women with early breast cancer could be offered a drug to stop the cancer returning, after the medicines watchdog approved its use in England.
Up to 4,000 patients a year could be given ribociclib alongside hormone therapy, for hormone receptor-positive, HER2-negative early breast cancer, which despite initial treatment has a higher risk of returning.
Cancer present in at least four lymph nodes.
Cancer present in one to three lymph nodes that is either grade 3 (more advanced), or has a primary tumour at least 5cm in size.
Continue reading...
By Anna Bawden Health and social affairs corespondent
Drug that cuts risk of breast cancer returning is approved for use in England to Continue reading...
NHS Forums - For NHS Staff | Patient Forums
